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Cost-effectiveness of influenza 
vaccination for elderly people living in 
the community
Key Messages
1. Influenza vaccination of elderly 
people living in the community 
was cost-effective from a 
societal perspective but did not 
cut publicly funded medical 
costs or total medical costs.
2. For the oldest group (≥75 
years) living in the community, 
influenza vaccination can cut 
publicly funded medical costs 
if the total vaccination cost per 
head is HK$39.6 or less.
3. Influenza vaccination is cost-
effective if the value of increasing 
an elderly person’s lifespan for 
a year at most is measured as 
HK$68 047 or more.
Hong Kong Med J 2009;15(Suppl 6):S44-7
Introduction
Influenza is one of the leading causes of respiratory infection. It is a highly 
contagious viral infection that affects 10 to 20% of the population every year.1 
Influenza generates both medical expenses, from resource use, and societal costs, 
due to lost productivity and mortality.
 Older people are particularly vulnerable to influenza infection and its 
complications can result in serious illness and death. Some countries recommend 
an annual influenza vaccination for older and high-risk groups because it is the most 
effective means of preventing influenza and reducing the impact of epidemics.2
 Since 1998, the Department of Health in Hong Kong has been providing free 
annual influenza vaccination to older people living in residential care homes.3 In 
addition, mainly since the outbreak of severe acute respiratory syndrome (SARS) 
in 2003, the Department of Health and non-governmental organisations have 
also provided free or low-cost annual influenza vaccinations to older people.
 Studies from other countries have shown that influenza vaccination in older 
people is cost-effective and can be cost saving for the health care provider.4 These 
studies are not directly applicable to Hong Kong with its different influenza 
seasonal pattern, health care cost structure, and relatively healthy older people.5 
The only study on the cost-effectiveness of influenza vaccination in Hong Kong 
published to date concluded that influenza vaccination was not cost-effective in 
any age-group.6 That study was based on a limited survey that found no additional 
risk of hospitalisation from the complications of influenza in older people and no 
influenza-related mortality in older people in Hong Kong. Subsequent analyses 
of influenza-related hospitalisation and mortality suggest that neither of these 
assumptions is appropriate.7 Thus, there is a need to conduct a local evaluation of 
the cost-effectiveness of influenza vaccination among older people in the Hong 
Kong community, taking into account the latest information on the impact of 
influenza in Hong Kong.
Aim
We evaluated the cost-effectiveness of influenza vaccination in Hong Kong for 
people aged 65 years and over living in the community. We also considered the 
following subsidiary questions:
1. Would a publicly funded influenza vaccination programme be cost saving?
2. What is the maximum cost per head of influenza vaccination at which a 
publicly funded influenza vaccination programme in older people would 
become cost saving?
3. What is the value of a life at which a publicly funded influenza vaccination 
programme in older people would break even?
4. Are there differences in cost-effectiveness or cost saving of medical costs in 
those aged 65 to 74 years and those 75 years and over?
Methods
This study was conducted from August 2004 to July 2005. We evaluated the 
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cost-effectiveness of an influenza vaccination programme 
by comparing the dollar value of the benefits obtained 
with the cost of a vaccination programme over 1 year, 
as influenza vaccinations are repeated annually. We 
considered (1) a comprehensive vaccination programme, 
where vaccination was centrally provided in the autumn, 
and (2) an opportunistic programme, where older people 
visiting a doctor for a reason other than cold, ‘flu’, or fever 
between October and December were offered an influenza 
vaccination. These programmes have different costs and 
uptakes.
 Given concerns over avian influenza and SARS we 
assumed a high uptake rate of 90% for a centrally provided 
vaccination, but travel costs for the older people concerned. 
An opportunistic programme generates no additional travel 
costs for the older people vaccinated, but there are additional 
costs involved in refunding the private general practitioners 
who administered the vaccine on an opportunistic basis to 
90% of those who made an appropriate doctor visit in the 
relevant months.
 The effectiveness of influenza vaccination as a means 
of preventing influenza was estimated from the most recent 
meta-analysis.8 Table 1 summarises the information used to 
cost an influenza vaccination programme and to estimate its 
benefits.
 Excess mortality, admissions to hospital, visits to a 
general practitioner, and number of cases where self-care 
was used for influenza-related illness were estimated from 
published studies and local survey data.7 Unit costs were 
obtained from routine data and local surveys. Table 2 
summarises the information used to cost influenza-related 
illness and shows the number of deaths, hospitalisations, 
doctor consultations, and self-care episodes estimated to be 
associated with influenza annually. The risk of influenza-
related mortality or hospitalisation is higher in the older 
age-group.
 We took three perspectives on costs and benefits (1) 
societal (2) personal or individual and (3) government or 
publicly funded health care. Societal costs and benefits 
included mortality, lost productivity, public and private use 
of medical resources, and personal expenses, such as travel 
costs.
 We carried out a probabilistic sensitivity analysis to 
identify the maximum vaccination cost at which influenza 
vaccination would be cost saving. We carried out our 
analysis for all older people in Hong Kong who live in the 
community, separated into two age-groups. Of the 729 200 
elderly people in Hong Kong, we estimated that 447 190 
aged 65 to 74 years and 237 222 aged 75 years and above 
lived in the community.9 Costs relate to the year 2000 and 
are in Hong Kong dollars (HK$).
Results
Cost of influenza
We estimated the total annual cost of influenza in older 
people living in the community as HK$9068 million, of 
which HK$60.7 million is publicly funded medical costs 
(Table 3). This is equivalent to HK$13 250 per head, and 
HK$88.6 per head in public health care costs.
Cost of vaccination
In a comprehensive programme reaching 90% of older 
people in the community, the total vaccination cost would 
be HK$40 million (Table 4). This is equivalent to a cost per 
person vaccinated of HK$64, including HK$57 in health 
care costs, HK$2 in lost productivity and HK$5 in personal 
Age-group (years)
65-74 ≥75
Vaccination cost
Influenza vaccination HK$25
Staff costs HK$25
Administration HK$6.5
Refund system for opportunistic 
programme only
HK$6.5
Lost productivity HK$3.6 N/A
Travel cost for comprehensive 
programme only
HK$5.6 HK$4.6
Vaccine uptake
Comprehensive programme 90%
Opportunistic programme 62% 76%
Vaccine effectiveness in preventing
Self-care cases 5%
Doctor consultations 5%
Hospitalisations* 22-27%
Mortality† 47%
Table 1. Vaccination cost, uptake, and effectiveness
* 22% for respiratory diseases, 24% for cardiac diseases, and 27% for 
pneumonia and influenza
† 47% for all-cause mortality
Age-group (years)
65-74 ≥75
Deaths
Value of life HK$10 million
Annual number due to ‘flu’ 272 628
Hospital use
Cost per bed-day HK$3132
Annual admissions due to ‘flu’ 759  1321
Length of stay* Various Various
Doctor visits
Unit cost (public) HK$251
Unit cost (private) HK$164
Travel cost HK$5.6 HK$4.6
No. of visits due to ‘flu’ 14 340 6464
Self-care
Western medicine cost HK$134 HK$61
Chinese medicine cost HK$79 HK$41
No. using self-care for ‘flu’ 34 901 19 656
Lost productivity
Value of work-time lost per worker HK$912 N/A
Table 2. Annual mortality and morbidity associated with 
influenza in older people and unit costs
* The length of stay varies depending on the type of disease
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costs. In an opportunistic programme in which 62% of 
those aged 65 to 74 years and 76% of those aged 75 years 
and over are vaccinated, the total vaccination cost would be 
HK$29 million or HK$63 per person vaccinated and this 
involves health care costs only.
Monetary benefits from influenza vaccination
A comprehensive vaccination programme would yield 
benefits of HK$3824 million, or HK$6207 per person 
vaccinated (Table 4). Most of this is from avoided mortality. 
The savings in public health care costs are HK$13 million or 
HK$21 per person vaccinated. An opportunistic programme 
yields savings in public health care of HK$10 million or 
HK$23 per person vaccinated.
Cost-effectiveness of influenza vaccination
The net benefits for both types of programme are negative 
from a governmental perspective but positive from a 
societal perspective. Vaccination would, on average, cut 
medical costs (from the government’s perspective) in the 75 
years and over age-group if the vaccination cost per person 
was HK$40 or less. For the 65 to 74 years age-group, 
vaccination would not reduce public health care costs even 
if the vaccination cost per person were as low as HK$15.
Breakeven value of life
For vaccination to be cost-effective, the value placed on saving 
a life would have to be at least HK$16 947 for those aged 75 
years and older and at least HK$186 243 for those aged 65 
to 74 years. If we put the age-groups together, the value of 
saving the life of anyone aged 65 years or older living in the 
community would have to be at least HK$68 047.
Discussion
Vaccinating people living in the community against 
influenza is cost-effective from a societal perspective. 
Most of the cost reductions from a vaccination programme 
come from mortality reductions. Vaccination does not save 
health care costs at the estimated cost of vaccination used 
in the analysis. These findings are consistent with some 
overseas studies.10 The results are not surprising because 
hospitalisation rates for influenza-related diseases in older 
people in Hong Kong appear to be lower than those observed 
elsewhere, making potential benefits from vaccination also 
lower. Local people also have lower mortality rates from 
cardiovascular disease and lower lifetime rates of smoking, 
which could contribute to them being less vulnerable to the 
cardiorespiratory complications of influenza.11
 We used a value of life of HK$10 million in this study. 
The analysis shows us that vaccination is still cost-effective 
from a societal perspective at values of life much lower than 
this.
Conclusion
Vaccinating elderly people living in the community against 
influenza was found to be cost-effective from a societal 
perspective but not from a governmental perspective 
at the values of costs and benefits used in this analysis. 
Nonetheless, influenza vaccination in older people (≥75 
Perspective Total
Personal Public Other societal Societal
Deaths (million) HK$9000 HK$9000
Hospitalisation (million) HK$0.1 HK$60.3 HK$0.2 HK$60.7
Out-patient (million) HK$3.3 HK$0.3 HK$1.2 HK$4.9
Self-care (million) HK$1.7 HK$1.4 HK$3.1
Total (million) HK$5.1 HK$60.7 HK$9002 HK$9068
Cost per head HK$7.5 HK$88.6 HK$13 154.1 HK$13 250
Table 3. Cost of influenza in older people living in the community
Perspective (HK$) Comprehensive programme (90% uptake) Opportunistic programme (62% and 76% uptake, respectively of 
those aged 65-74 and ≥75 years)
Personal Government Indirect 
costs
Societal Personal Government Indirect costs Societal
Benefits
Deaths 3 810 000 000 3 030 000 000
Hospitalisations 32 358 13 129 999 43 025 13 205 382 25 486 10 360 305 29 640 10 415 431
Out-patient 149 030 14 471 55 798 219 299 109 865 10 625 38 438 158 928
Self-care 75 437 - 62 470 137 907 53 706 43 035 96 741
Total benefits 256 825 13 144 470 161 293 3 823 562 588 189 057 10 370 930 111 113 3 040 671 100
Benefits per person vaccinated 0.4 21.3 0.3 6207.4 0.4 22.7 0.2 6645.6
Costs 3 235 938 34 802 371 1 450 080 39 488 389 28 825 450 28 825 450
Cost per person vaccinated 5.3 56.5 2.4 64.1 63.0 63.0
Net benefits -2 979 113 -21 657 901 3 784 074 199 189 057 -18 454 520 3 011 845 650
Per person net benefits -4.9 -35.2 6143.3 0.4 -40.3 6582.6
Table 4. Monetary benefits and costs of influenza vaccination for all people aged 65 years and over living in the community: 
from personal, governmental, and societal perspectives
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years) in the community would be cost saving from the 
governmental (public health care) perspective if the cost of 
vaccinating each person, including the cost of the vaccine 
and its administration, was HK$39.6 or less. Furthermore, 
vaccination would be cost-effective from a societal 
perspective if the value of a life of a person aged over 65 
years were put at HK$68 047 or more.
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